GlassScriptPhysician profile
David N Rios
NPI 1083797435
$8,416.81
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $1,469 · 2021: $2,568 · 2022: $1,833 · 2023: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.83 | 2019-2023 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $927.87 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $923.57 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $604.98 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $346.68 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.44 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $297.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $285.38 | 2019-2023 | |
| Amgen INC. | $267.83 | 2019-2023 | Repatha, Otezla |
| Eisai INC. | $252.20 | 2020-2022 | |
| Novo Nordisk INC | $243.19 | 2020-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $236.97 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Allergan, INC. | $191.78 | 2019-2020 | |
| Astellas Pharma US INC | $191.43 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $182.58 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.